2006
2006 Press Releases
Exactech Q3 Revenue Up 13% to $24.3M;Net Income $1.8M or $0.16 EPS
Gainesville, FL, October 30, 2006 -- Exactech, Inc. (Nasdaq: EXAC) announced today that revenue for the third quarter of 2006 increased 13% to $24.3 million from $21.5 million in the third quarter of 2005. Diluted earnings per share for the quarter was $0.16 based on net income of $1.8 million, compared to diluted earnings per share of $0.15 on net income of $1.7 million for the third quarter of 2005.
Exactech Knee Designer and Board Member Albert Burstein Receives Lifetime Achievement Award
Gainesville, FL, October 12, 2006 -- Exactech, Inc. (Nasdaq: EXAC), announced today that Albert Burstein, Ph.D, a member of the board and the lead design engineer for the company’s Optetrak® knee implant, received the Lifetime Achievement Award from the International Society for Technology in Arthroplasty (ISTA) at its annual symposium in New York this week.
Exactech Gains FDA Clearance for DBM with Bone Chips, OptecureTM +CCC
Gainesville, FL, September 26, 2006 -- Exactech, Inc. (Nasdaq: EXAC), a producer and distributor of bone and joint restoration products including orthopaedic implants and biologic materials, announced today that the Food and Drug Administration (FDA) has issued 510(k) clearance for a new formulation of the company’s OptecureTM allograft which includes cortical cancellous bone chips.
Exactech Asserts Superiority Regarding Knee Replacement Performance
Gainesville, FL, July 31, 2006 -- Exactech, Inc. (Nasdaq: EXAC) confirmed today that its Optetrak® knee system with net compression molded polyethylene proved to have wear characteristics that are superior to those reported by competitors. Responding to competitive claims regarding knee replacement performance, Exactech cited laboratory testing that simulates normal walking conditions and long-standing data that clearly demonstrated the superiority of the Optetrak knee to those cited in recent competitive claims. Additionally, the Optetrak knee system has met the ultimate test—excellent clinical experience.
Exactech Q2 Revenue Up 11% to $26.6M. Net Income $2.1M or $0.18 EPS
Gainesville, FL, July 31, 2006 -- Exactech, Inc. (Nasdaq: EXAC) announced today that revenue for the second quarter of 2006 increased 11% to $26.6 million from $23.9 million in the second quarter of 2005. Diluted earnings per share for the quarter was $0.18 based on net income of $2.1 million, compared to diluted earnings per share of $0.16 on net income of $1.9 million for the second quarter of 2005.
Exactech Adds Cemented Stem to Novation™ Hip System
Gainesville, FL, July 20, 2006 -- Exactech (Nasdaq: EXAC), a producer and distributor of bone and joint restoration products including orthopaedic implants and biologic materials, announced today that it has added a cemented stem to its Novation™ Hip System.
Exactech Announces FDA Clearance for U.S. Distribution of InterSpace™ Shoulder Pre-formed Antibiotic Bone Cement Spacer
Gainesville, FL, June 19, 2006 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including orthopaedic implants and biologic materials, announced today that the U.S. Food and Drug Administration (FDA) has cleared for distribution the only pre-formed cement shoulder spacer containing antibiotic available in the United States.
Exactech’s Equinoxe™ Shoulder System Featured in Live Surgery Broadcast at Major Orthopaedics Conference
Gainesville, FL, May 19, 2006 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including orthopaedic implants and biologic materials, will feature its Equinoxe™ shoulder system at a major orthopaedic conference, Current Concepts in Orthopaedic Surgery, this weekend in Las Vegas. More than 1,000 surgeons from around the world are expected to participate in this educational program.
Exactech Q1 Revenue Up 12% to $25.4M; Net Income Up 36% to $1.6M or $0.14 EPS
Gainesville, FL, April 25, 2006 -- Exactech, Inc. (Nasdaq: EXAC) announced today that revenue for the first quarter of 2006 increased 12% to $25.4 million, from $22.6 million in the first quarter of 2005. Net income for the quarter was $1.6 million, or $0.14 per diluted share, a gain of 36% over $1.2 million, or $0.10 per diluted share, in the first quarter of 2005.
Exactech Presents at Orthopedic Financial Conference, Opens Exhibit at AAOS
Gainesville, FL, March 21, 2006 -- Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including orthopaedic implants and biologic materials, presented today at the First Albany Capital Small-Cap Orthopedic Conference held in conjunction with the American Academy of Orthopedic Surgeons (AAOS) being held all week in Chicago.
Exactech 2005 Revenue Up 11% to $91M;Net Income $6.6M or $0.57 EPS
Gainesville, FL, February 27, 2006 -- Exactech, Inc. (Nasdaq: EXAC) announced today that revenue for fiscal year 2005 increased 11.2% to $91.0 million from $81.8 million in 2004. Net income for the year was $6.6 million or $0.57 diluted earnings per share for the year, compared with net income of $7.3 million or $0.63 diluted earnings per share during 2004.
